| Predictors of immunotherapy-induced immune-related adverse events A Kartolo, J Sattar, V Sahai, T Baetz, JM Lakoff Current Oncology 25 (5), 403-410, 2018 | 104 | 2018 |
| The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population J Sattar, A Kartolo, WM Hopman, JM Lakoff, T Baetz Journal of geriatric oncology 10 (3), 411-414, 2019 | 67 | 2019 |
| A discussion of the use of virtual reality in dementia L Garcia, A Kartolo, E Méthot-Curtis Virtual reality in psychological, medical and pedagogical applications, 123-136, 2012 | 50 | 2012 |
| Motivation and preferences of exercise programmes in patients with inoperable metastatic lung cancer: a need assessment A Kartolo, S Cheng, T Petrella Supportive Care in Cancer 24, 129-137, 2016 | 36 | 2016 |
| Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy A Kartolo, R Holstead, S Khalid, J Emack, W Hopman, A Robinson, ... Immunotherapy 12 (11), 785-798, 2020 | 32 | 2020 |
| A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors A Kartolo, H Feilotter, W Hopman, AS Fung, A Robinson Cancer Treatment and Research Communications 27, 100330, 2021 | 23 | 2021 |
| Case based learning teaching methodology in undergraduate health sciences K Brown, M Commandant, A Kartolo, C Rowed, A Stanek, H Sultan, ... | 22 | 2012 |
| Long-term toxicities of immune checkpoint inhibitor (ICI) in melanoma patients J Tong, A Kartolo, C Yeung, W Hopman, T Baetz Current Oncology 29 (10), 7953-7963, 2022 | 19 | 2022 |
| Safety and clinical outcomes of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases C Yeung, A Kartolo, R Holstead, GT Moffat, L Hanna, W Hopman, J Lakoff, ... Journal of Immunotherapy 44 (9), 362-370, 2021 | 15 | 2021 |
| Impact of baseline corticosteroids on immunotherapy efficacy in patients with advanced melanoma A Kartolo, J Deluce, R Holstead, W Hopman, J Lenehan, T Baetz Journal of Immunotherapy 44 (4), 167-174, 2021 | 15 | 2021 |
| Safety of immunotherapy rechallenge after immune-related adverse events in patients with advanced cancer A Kartolo, R Holstead, S Khalid, J Emack, W Hopman, T Baetz Journal of Immunotherapy 44 (1), 41-48, 2021 | 14 | 2021 |
| Impact of the development of immune related adverse events in metastatic melanoma treated with PD-1 inhibitors RG Holstead, BA Kartolo, WM Hopman, TD Baetz Melanoma Research 31 (3), 258-263, 2021 | 13 | 2021 |
| Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study A Kartolo, H Shah, W Hopman, AS Fung, P Wheatley-Price, A Robinson Cancer Treatment and Research Communications 29, 100496, 2021 | 13 | 2021 |
| Virtual reality in psychological, medical and pedagogical applications L Garcia, A Kartolo, E Méthot-Curtis Rijeka: Intech, 123-136, 2012 | 10 | 2012 |
| Adjuvant immune checkpoint inhibition in muscle-invasive bladder cancer: is it ready for prime time? A Kartolo, W Kassouf, FE Vera-Badillo European Urology 80 (6), 679-681, 2021 | 9 | 2021 |
| Emergency department utilization for patients receiving immune checkpoint inhibitors: a retrospective analysis of identification and outcomes for those presenting for immune … R Holstead, A Kartolo, T Baetz Current Oncology 28 (1), 52-59, 2020 | 9 | 2020 |
| Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma A Kartolo, R Holstead, W Hopman, T Baetz Immunotherapy 13 (3), 217-225, 2021 | 8 | 2021 |
| Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma C Yeung, A Kartolo, J Tong, W Hopman, T Baetz Immunotherapy 15 (11), 819-826, 2023 | 7 | 2023 |
| Should the control arms of randomized trials have an expiry date? A Kartolo, B Gyawali Nature Reviews Clinical Oncology 19 (7), 425-426, 2022 | 6 | 2022 |
| Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors A Kartolo, C Yeung, GT Moffat, L Hanna, W Hopman, T Baetz Immunotherapy 14 (1), 23-30, 2022 | 6 | 2022 |
